Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin

NCT04119453 is registered in ClinicalTrials.gov with Elevar Therapeutics as lead sponsor.

NCT NCT04119453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04119453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Lead sponsor
Elevar Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
January 22, 2020
Completion date
June 28, 2023
Enrollment
80 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma